Angiogenesis and pulmonary hypertension: A unique process in a unique disease

Antioxidants and Redox Signaling

Volumn 4, Issue 5, 2002, Pages 833-843

  Tuder, Rubin M ^a   Voelkel, Norbert F ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; COLLAGEN; ELASTASE; ENDOSTATIN; ENDOTHELIN; HYPOXIA INDUCIBLE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN SYNTHASE; RANTES; SEROTONIN; TENASCIN; THALIDOMIDE; THROMBOSPONDIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; GENE MUTATION; HUMAN; LUNG ARTERY PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; TUMOR SUPPRESSOR GENE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; CELL GROWTH; CELL SELECTION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; MALIGNANT NEOPLASM; MEDIAL SMOOTH MUSCLE CELL; SMOOTH MUSCLE CELL; VASCULAR REMODELING;

ANIMALS; CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; NEOVASCULARIZATION, PATHOLOGIC; PULMONARY ARTERY; TUNICA INTIMA; TUNICA MEDIA;

EID: 0036774342     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/152308602760598990     Document Type: Review

References (72)

1. Caslin AW, Heath D, Madden B, Yacoub M, Gosney JR, and Smith P. The histopathology of 36 cases of plexogenic pulmonary arteriopathy. Histopathology 16: 9-19, 1990.
2. Chandra J, Samali A, and Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 29: 323-333, 2000.
3. Chazova I, Loyd JE, Newman JH, Belenkov Y, and Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 146: 389-397, 1995.
4. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, and Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70-75, 1992.
5. Cool CD, Kennedy D, Voelkel NF, and Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28: 434-442, 1997.
6. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, and Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155: 411-419, 1999.
7. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, and Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6: 698-702, 2000.
8. Cowan KN, Jones PL, and Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105: 21-34, 2000.
9. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, and Knowles JA. Familial primary pulmonary hypertension (gene PPHI) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737-744, 2000.
10. DeRuiter MC, Poelmann RE, VanMunsteren JC, Mironov V, Markwald RR, and Gittenberger-de Groot AC. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res 80: 444-451, 1997.
11. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, and Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105: 1555-1562, 2000.
12. Esteller M, Corn PG, Baylin SB, and Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
13. Fanburg BL and Lee SL. A role for the serotonin transporter in hypoxia-induced pulmonary hypertension. J Clin Invest 105: 1521-1523, 2000.
14. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, and Semenza GL. Reciprocal positive regulation of hypoxiainducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3919, 1999.
15. Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest 72: 615-618, 1995.
16. Folkman J. Angiogenic gene therapy. Proc Natl Acad Sci USA 95: 9064-9066, 1998.
17. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao BF, Loyd JE, Tuder RM, and Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension - A gene microarray analysis. Circ Res 88: 555-562, 2001.
18. Giaid A and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214-221, 1995.
19. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 100: 57-70, 2000.
20. Hatva E, Böhling T, Jääskeläinen J, Graziella PM, Haltia M, and Alitalo K. Vascular endothelial growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 148: 763-775, 1996.
21. Heath D and Edwards JE. The pathology of pulmonary hypertensive disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal changes. Circulation 18: 533-547, 1958.
22. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, and Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249-254, 1995.
23. Hosoda Y. Pathology of pulmonary hypertension: A human and experimental study. Pathol Int 44: 241-267, 1994.
24. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, and Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151: 1628-1631, 1995.
25. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G, and Emilie D. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Resp J 11: 554-559, 1998.
26. Ionov Y, Yamamoto H, Krajewski S, Reed JC, and Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 97: 10872-10877, 2000.
27. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, and Baylin SB. Methylation of the oestrogen receptor CpG islands links aging and neoplasia in the human colon. Nat Genet 7: 536-540, 1994.
28. Jiang BH, Agani F, Passaniti A, and Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res 57: 5328-5335, 1997.
29. Jones PL and Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 79: 1131-1142, 1996.
30. Kuhn K, Loyd J, Wheeler L, Phillips J III, Newman J, and Lane K. Phenotypic manifestations of FPPH correlate with BMPRII genotype. Am J Respir Crit Care Med 163: A113, 2001.
31. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Philips JA 3rd, Loyd JE, Nichols WC, and Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial pulmonary hypertension. The International PPH Consortium. Nat Genet 26: 81-84, 2000.
32. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, and Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101: 927-934, 1998.
33. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, and Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88: 9267-9271, 1991.
34. Massague J, Blain SW, and Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
35. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, and Bush HL Jr. Decreased type1/TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest 96: 2667-2675, 1999.
36. McDonald PP, Fadok VA, Bratton D, and Henson PM. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells. J Immunol 163: 6164-6172, 1999.
37. 3H-thymidine by cells of the rat pulmonary arteries and alveolar wall. Am J Pathol 96: 51-70, 1979.
38. Morse JH and Barst RJ. Detection of familial primary pulmonary hypertension by genetic testing. N Engl J Med 337: 202-203, 1997.
39. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, and Isner JM. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270: 31189-31195, 1995.
40. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, Siemieniak DR, Wheeler L, Phillips JA, Newman JH, Conneally PM, Ginsburg D, and Loyd JE. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 15: 277-280, 1997.
41. Rabinovitch M. EVE and beyond, retro and prospective insights. Am J Physiol 277: L5-L12, 1999.
42. Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, Biggar RJ, and Zhuang Z. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 336: 988-993, 1997.
43. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, and Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
44. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578, 1999.
45. Smith P and Heath D. Electron microscopy of the plexiform lesion. Thorax 34: 177-186, 1979.
46. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon GG, Waltenberger J, Voelkel NF, and Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438, 2001.
47. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, and Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 37: 741-745, 2000.
48. Tuder RM and Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med 132: 16-24, 1998.
49. Tuder RM, Groves BM, Badesch DB, and Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275-285, 1994.
50. Tuder RM, Cool CD, Jennings C, and Voelkel NF. Interstitial Lung Disease. Hamilton, Ontario: B.C. Decker, 1998, pp. 251-263.
51. Tuder RM, Lee SD, and Cool CD. Histopathology of pulmonary hypertension. Chest 114: 1S-6S, 1998.
52. Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, and Voelkel NF. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 158: 1999-2001, 1998.
53. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch DB, and Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932, 1999.
54. Tuder RM, Chacon M, Alger LA, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci MW, Semenza GL, Yacoub M, Polak JM, and Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 195: 367-374, 2001.
55. Tuder RM, Yeager ME, Geraci M, Golpon HA, and Voelkel NF. Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene. Eur Respir J 17: 1065-1069, 2001.
56. Voelkel NF. Appetite suppressants and pulmonary hypertension. Thorax 52: S63-S67, 1997.
57. Voelkel NF and Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Resp J 8: 2129-2138, 1995.
58. Voelkel NF and Tuder RM. Hypoxia-induced pulmonary vascular remodeling - A model for what human disease? J Clin Invest 106: 733-738, 2000.
59. Voelkel NF, Hoeper M, Maloney J, and Tuder RM. Vascular endothelial growth factor in pulmonary hypertension. Ann N Y Acad Sci 796: 186-193, 1996.
60. Voelkel NF, Tuder RM, Wade K, Hoper M, Lepley RA, Goulet JL, Koller BH, and Fitzpatrick F. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 97: 2491-2498, 1996.
61. Voelkel NF, Cool CD, Lee SD, Wright L, Geraci MW, and Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 114: 225S-230S, 1999.
62. Wagenvoort CA and Wagenvoort N. Pathology of Pulmonary Hypertension. New York: John Wiley & Sons, 1977, pp. 17-55.
63. Wagenvoort CA and Wagenvoort N. Pathology of Pulmonary Hypertension. New York: John Wiley & Sons, 1977, pp. 119-142.
64. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, and Heldin CH. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995, 1994.
65. Weindel K, Marme D, and Weich HA. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun 183: 1167-1174, 1992.
66. Wright L, Tuder RM, Cool CD, Lepley RA, and Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 157: 219-229, 1998.
67. Xin X, Yang S, Kowalski J, and Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-9121, 1999.
68. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T, Naito M, Nakao K, and Nishikawa S. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 408: 92-96, 2000.
69. Yeager ME, Voelkel NF, and Tuder RM. Mutational analysis of endothelial cell TGF-b receptor type II in plexiform lesions of patients with primary pulmonary hypertension. Circulation 100: 1-587, 1999.
70. Yeager ME, Halley GR, Golpon HA, Voelkel NF, and Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 88: e8-e11, 2001.
71. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, and Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275: L818-L826, 1998.
72. Zaidi SH, You XM, Ciura S, O'Blenes S, Husain M, and Rabinovitch M. Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice. J Clin Invest 105: 1687-1695, 2000.